title: Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension.
abstract: Phosphodiesterase 5 (PDE 5) inhibitors are selective inhibitors of the enzyme PDE 5, which catalyzes the hydrolysis of cyclic guanosine monophosphate (cGMP), a potent vasodilator and nitric oxide (NO) donor, to its corresponding metabolites (monophosphates). The enzyme PDE 5 is widely distributed in the body, including the heart and blood vessels. Because of its distribution, it was hypothesized that its inhibition could lead to significant coronary vasodilation, which would benefit patients with coronary artery disease (CAD). This hypothesis led to the development of PDE 5 inhibitors with the first being sildenafil citrate. Subsequent studies with sildenafil in patients with CAD demonstrated a modest cardiovascular effect, but a potent action on penile erection in men, resulting in sildenafil becoming a first-line therapy of erectile dysfunction (ED). Subsequently, two more PDE 5 inhibitors (vardenafil and tadalafil) were developed and approved by the Food and Drug Administration (FDA) for the treatment of ED. Recent studies have shown several pleiotropic beneficial effects of PDE 5 inhibitors in patients with CAD, hypertension, heart failure, pulmonary arterial hypertension, diabetes mellitus and Raynaud's phenomenon. Side effects and interactions of PDE 5 inhibitors with other drugs have been minimal, with the exception of their coadministration with nitrates, which could lead to severe vasodilation and hypotension and therefore, their coadministration is prohibited. All these pleiotropic cardiovascular effects of PDE 5 inhibitors and their drug interactions will be discussed in this concise review in the context of the American College of Cardiology / American Heart Association guidelines and the recent developments in this field.
authors.affiliation: University of Oklahoma College of Medicine, 5700 Mistletoe Court, Oklahoma City, OK, 73142, USA, schrysant@yahoo.com.
authors.forename: Steven G
authors.initials: SG
authors.lastname: Chrysant
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy*; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors
references.citation: J Am Coll Cardiol. 2013 Feb 12;61(6):599-610
references.pmid: 23219298
references.citation: J Cardiovasc Pharmacol. 2007 Dec;50(6):670-6
references.pmid: 18091584
references.citation: Circulation. 2002 Aug 27;106(9):1097-103
references.pmid: 12196335
references.citation: Am J Cardiol. 2005 Nov 15;96(10):1436-40
references.pmid: 16275194
references.citation: Circulation. 2005 Nov 8;112(19):2980-5
references.pmid: 16275885
references.citation: J Urol. 2002 Oct;168(4 Pt 1):1332-6
references.pmid: 12352386
references.citation: Eur Heart J. 2003 Dec;24(24):2206-12
references.pmid: 14659772
references.citation: FASEB J. 2001 Aug;15(10):1718-26
references.pmid: 11481219
references.citation: Am J Hypertens. 2004 Dec;17(12 Pt 1):1135-42
references.pmid: 15607620
references.citation: Chest. 2011 Nov;140(5):1274-1283
references.pmid: 21546436
references.citation: J Sex Med. 2011 Oct;8(10):2904-11
references.pmid: 21771281
references.citation: Clin Pharmacol Ther. 2007 Apr;81(4):503-9
references.pmid: 17301734
references.citation: Prog Nucleic Acid Res Mol Biol. 1999;63:1-38
references.pmid: 10506827
references.citation: JAMA. 2005 Dec 21;294(23):2996-3002
references.pmid: 16414947
references.citation: Am J Respir Crit Care Med. 2011 Jun 15;183(12):1723-9
references.pmid: 21471085
references.citation: Am J Physiol Heart Circ Physiol. 2008 Mar;294(3):H1398-406
references.pmid: 18223185
references.citation: J Sex Med. 2010 Feb;7(2 Pt 1):758-68
references.pmid: 19912487
references.citation: Arch Intern Med. 2002 Jun 24;162(12):1349-60
references.pmid: 12076233
references.citation: Diabet Med. 2008 Feb;25(2):138-46
references.pmid: 18290855
references.citation: J Sex Med. 2005 Jan;2(1):40-50; discussion 50-2
references.pmid: 16422903
references.citation: Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H1263-9
references.pmid: 12181158
references.citation: Circulation. 2003 Jul 15;108(2):239-44
references.pmid: 12860892
references.citation: Gene. 2001 Jan 24;263(1-2):1-16
references.pmid: 11223238
references.citation: Biochem Biophys Res Commun. 2000 May 19;271(3):575-83
references.pmid: 10814504
references.citation: J Androl. 2002 Nov-Dec;23(6):763-71
references.pmid: 12399521
references.citation: Clin Pharmacol Ther. 2012 May;91(5):813-9
references.pmid: 22453196
references.citation: J Biol Chem. 2000 Oct 6;275(40):31469-79
references.pmid: 10906126
references.citation: J Mol Cell Cardiol. 2006 Mar;40(3):405-11
references.pmid: 16480739
references.citation: Circulation. 2010 Apr 6;121(13):1474-83
references.pmid: 20308615
references.citation: N Engl J Med. 2002 Sep 26;347(13):1001-8
references.pmid: 12324557
references.citation: J Sex Med. 2005 May;2(3):407-14
references.pmid: 16422873
references.citation: Expert Opin Investig Drugs. 2009 Jan;18(1):23-9
references.pmid: 19053879
references.citation: J Androl. 2012 Mar-Apr;33(2):176-80
references.pmid: 21680809
references.citation: Am J Cardiol. 2004 Jan 15;93(2):147-53
references.pmid: 14715338
references.citation: Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7071-6
references.pmid: 10359840
references.citation: Am J Hypertens. 2001 Jan;14(1):70-3
references.pmid: 11206684
references.citation: Curr Hypertens Rep. 2002 Jun;4(3):202-10
references.pmid: 12003702
references.citation: Angiology. 2006 Jan-Feb;57(1):47-52
references.pmid: 16444456
references.citation: Life Sci. 2006 Feb 2;78(10):1103-7
references.pmid: 16297411
references.citation: Circulation. 2007 Oct 2;116(14):1555-62
references.pmid: 17785618
references.citation: J Am Coll Cardiol. 2012 Aug 21;60(8):768-74
references.pmid: 22818063
references.citation: Hypertension. 2010 Jul;56(1):62-7
references.pmid: 20479335
references.citation: Front Biosci. 2007 Jan 01;12:1024-33
references.pmid: 17127357
references.citation: Rheumatology (Oxford). 2010 Dec;49(12):2420-8
references.pmid: 20837499
references.citation: Mayo Clin Proc. 2009 Feb;84(2):139-48
references.pmid: 19181648
references.citation: Am J Cardiol. 2013 Mar 4;111(5 Suppl):1A-16A; quiz 17A-19A
references.pmid: 23414683
references.citation: Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H827-36
references.pmid: 20543084
references.citation: J Mol Cell Cardiol. 2008 Jan;44(1):105-13
references.pmid: 18021798
references.citation: Circulation. 2009 Jun 9;119(22):2894-903
references.pmid: 19470885
references.citation: Ann Pharmacother. 2011 Dec;45(12):1551-8
references.pmid: 22116990
references.citation: Diabetes Metab. 2012 Feb;38(1):1-13
references.pmid: 22056307
references.citation: Int J Impot Res. 2007 Jan-Feb;19(1):55-61
references.pmid: 16858368
references.citation: J Am Coll Cardiol. 1999 Jan;33(1):273-82
references.pmid: 9935041
references.citation: J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12
references.pmid: 12475462
references.citation: Arch Intern Med. 2004 Mar 8;164(5):514-20
references.pmid: 15006828
references.citation: Br Med Bull. 2009;92:7-32
references.pmid: 19776034
references.citation: Am J Cardiol. 1999 Mar 4;83(5A):3C-12C
references.pmid: 10078537
references.citation: Biochem Biophys Res Commun. 1998 Jun 18;247(2):249-54
references.pmid: 9642111
references.citation: J Am Coll Cardiol. 2012 Jan 3;59(1):9-15
references.pmid: 22192662
references.citation: J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-S66
references.pmid: 19555859
references.citation: Circulation. 2004 Nov 9;110(19):3149-55
references.pmid: 15533876
references.citation: BMJ. 1990 Sep 22;301(6752):590-2
references.pmid: 2242457
references.citation: J Biol Chem. 1998 Jun 19;273(25):15559-64
references.pmid: 9624146
references.citation: N Engl J Med. 2000 Jun 1;342(22):1622-6
references.pmid: 10833207
references.citation: J Endocrinol Invest. 2011 Nov;34(10):738-41
references.pmid: 22234177
references.citation: Diabetes Res Clin Pract. 2007 Oct;78(1):136-40
references.pmid: 17374416
references.citation: Comp Biochem Physiol A Mol Integr Physiol. 2005 Oct;142(2):102-10
references.pmid: 16091305
references.citation: Diabetes Care. 2003 Mar;26(3):777-83
references.pmid: 12610037
references.citation: Am J Cardiol. 2003 Nov 6;92(9A):47M-57M
references.pmid: 14609623
references.citation: Am J Physiol Heart Circ Physiol. 2011 Jun;300(6):H2272-9
references.pmid: 21398594
references.citation: Hypertension. 1997 Jan;29(1 Pt 1):8-14
references.pmid: 9039073
references.citation: Am J Cardiol. 1999 Mar 4;83(5A):1C-2C
references.pmid: 10078536
references.citation: Arch Intern Med. 2006 Jan 23;166(2):231-3
references.pmid: 16432094
references.citation: J Sex Med. 2009 Mar;6(3):658-74
references.pmid: 19138362
references.citation: Biochem Biophys Res Commun. 1998 May 29;246(3):570-7
references.pmid: 9618252